FMP

FMP

Enter

CRSP - CRISPR Therapeutics ...

photo-url-https://images.financialmodelingprep.com/symbol/CRSP.png

CRISPR Therapeutics AG

CRSP

NASDAQ

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

42.12 USD

0.13 (0.309%)

CRSP Financial Statements

Year

2024

2023

2022

2021

CF from Operating Activities

-142.77M

-260.38M

-495.74M

538.97M

Net Income

-366.25M

-153.61M

-650.17M

377.66M

Depreciation & Amortization

19.26M

19.84M

24.17M

17.95M

Deferred Income Taxes

0

0

0

0

Stock Based Compensation

86.57M

81.03M

97.95M

102.39M

Change in Working Capital

156.27M

-193.59M

19.84M

26.86M

Accounts Receivable

175M

-200M

305k

-161k

Inventory

0

23.33M

0

-37.51M

Accounts Payable

0

-20.25M

5.16M

37.51M

Other Working Capital

-18.73M

3.33M

14.38M

27.02M

Other Non-Cash Items

-38.62M

-14.04M

12.47M

14.11M

CF from Investing Activities

-280.48M

374.65M

-258.65M

-1.04B

Investments in Property, Plant & Equipment

-1.9M

-9.47M

-37.19M

-81.7M

Net Acquisitions

0

0

221.47M

953.73M

Investment Purchases

-1.46B

-1.07B

-1.42B

-1.51B

Sales/Maturities of Investments

1.21B

1.45B

1.2B

555.6M

Other Investing Activites

-23.18M

-2.5M

-221.47M

-953.73M

CF from Financing Activities

331.98M

62.66M

38.59M

250.94M

Debt Repayment

0

0

0

0

Common Stock Issued

300.69M

32.72M

970k

213.27M

Common Stock Repurchased

0

0

0

0

Dividends Paid

0

0

0

0

Other Financing Activites

31.29M

29.94M

37.62M

37.68M

Free Cash Flow

-144.68M

-272.35M

-532.93M

457.27M

Operating Cash Flow

-142.77M

-260.38M

-495.74M

538.97M

Capital Expenditures

-1.9M

-11.97M

-37.19M

-81.7M

Cash at Beginning of Period

401.07M

224.06M

939.94M

1.19B

Cash at End of Period

309.78M

401.07M

224.06M

939.94M

Net Change In Cash

-91.29M

177.01M

-715.88M

-245.52M

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

-999.7M

-846.09M

-195.91M

-573.58M

Net Income

-366.25M

-153.61M

-650.17M

377.66M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-1.37B

-999.7M

-846.09M

-195.91M

Other Distributions

-366.25M

-153.61M

-650.17M

377.66M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

277.55M

305.94M

320.56M

312.04M

Annual Depreciation

0

19.84M

24.17M

17.95M

Capital Expenditure

-1.9M

-11.97M

-37.19M

-81.7M

Net PPE

279.45M

298.07M

333.57M

375.79M

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep